Zobrazeno 1 - 10
of 167
pro vyhledávání: '"I J, Mackie"'
Autor:
Ashish Goel, K.A. Balasubramanian, Sukesh Chandran Nair, I. J. Mackie, Elwyn Elias, CE Eapen, Uday Zachariah
Publikováno v:
Thrombosis Research
Publikováno v:
International Journal of Laboratory Hematology. 39:532-538
Summary Introduction A new prothrombin time reagent (Revohem™ PT) based on recombinant human tissue factor produced by the silkworm-baculovirus expression system was tested. The aim of this study was to compare the performance of the new PT reagent
Autor:
David A. Isenberg, Hannah Cohen, Sj Machin, Maria Efthymiou, I. J. Mackie, Deepa R. J. Arachchillage, A Chitolie, Munther A. Khamashta, Beverley J. Hunt
Publikováno v:
Journal of Thrombosis and Haemostasis. 14:2177-2186
Essentials Complement activation has a pathogenic role in thrombotic antiphospholipid syndrome (APS). Coagulation proteases such as factor Xa can activate complement proteins. Complement activation markers were elevated in anticoagulated thrombotic A
Autor:
Sj Machin, Mari Thomas, Raymond Camilleri, K. Manns, I. J. Mackie, W. Chen, Marie Scully, R. Liesner
Publikováno v:
Journal of Thrombosis and Haemostasis. 10:1792-1801
Background: ADAMTS13 mutations play a role in thrombotic thrombocytopenic purpura (TTP) pathogenesis. Objectives: To establish a phenotype-genotype correlation in a cohort of congenital TTP patients. Patients/Methods: Clinical history and ADAMTS13 ac
Autor:
Iain Moore, Neil McDougall, Lisa Strain, Timothy H.J. Goodship, James Tellez, Claire L. Harris, Kevin J. Marchbank, Marie Scully, J. H. Brown, Valerie Wilson, I. J. Mackie, John O'Grady, M. M. Tredger, Neil S. Sheerin
Publikováno v:
American Journal of Transplantation. 12:1632-1636
We report here a young female who underwent a successful deceased donor liver transplant for hepatic vein thrombosis. Five years after transplantation she developed postpartum atypical hemolytic uremic syndrome (aHUS). She did not recover renal funct
Publikováno v:
Thrombosis Research. 129:447-452
A persistently elevated level of factor VIII (FVIII) is an independent risk factor for venous thromboembolism (VTE). Although the pathophysiology of VTE is unclear, the involvement of thrombin generation (TG) has been postulated. Consequently this st
Publikováno v:
British Journal of Haematology. 157:47-58
This guidance updates and replaces the previous guideline on the investigation and management of antiphospholipid syndrome (APS) published in 2000 (Greaves et al, 2000), though where there have not been changes we refer back to them when appropriate.
Publikováno v:
Haemophilia. 17:252-256
von Willebrand's disease (VWD) is regarded as the most common congenital bleeding disorder, and although not available in all laboratories von Willebrand factor (VWF) activity is most frequently assessed as ristocetin cofactor (VWF:RCo). This test ca
Publikováno v:
Journal of Thrombosis and Haemostasis. 8:1201-1208
Summary. Background: Increasingly, patients with acute, idiopathic, antibody mediated thrombotic thrombocytopenic purpura (TTP) are being treated with rituximab to achieve a durable remission, however, there is the potential that it is removed by pla
Autor:
Marie Scully, Maria Teresa Canciani, Samuel J. Machin, I. J. Mackie, Flora Peyvandi, Laura E. Green, Anthony Lawrie
Publikováno v:
Vox Sanguinis. 99:232-238
Background Octapharma PPGmbH has recently modified its manufacturing process for solvent/detergent-treated plasma to incorporate a prion reduction step, in which a 3 log reduction has been demonstrated. The current study was undertaken to assess the